{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:46:42Z","timestamp":1788792402131,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients received PLD, cyclophosphamide, vincristine\/vindesine, plus prednisone every 3 weeks for up to 6 cycles. The primary endpoint was the objective response rate at the end of treatment (EOT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From September 2015 to January 2017, 40 patients were treated. At the EOT, objective response was achieved by 82.5% of patients, with 62.5% complete response. As of the cutoff date (September 26, 2023), median progression-free survival (mPFS) and overall survival (mOS) were not reached (NR). The 2-year, 5-year, and 8-year PFS rates were 55.1%, 52.0%, and 52.0%. OS rate was 80.0% at 2 years, 62.5% at 5 years, and 54.3% at 8 years. Patients with progression of disease within 24 months (POD24) had worse prognosis than those without POD24, regarding mOS (41.2 months vs NR), 5-year OS (33.3% vs 94.4%), and 8-year OS (13.3% vs 94.4%). Common grade 3-4 adverse events were neutropenia (87.5%), leukopenia (80.0%), anemia (17.5%), and pneumonitis (17.5%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This combination had long-term benefits and manageable tolerability, particularly with less cardiotoxicity, for aggressive PTCL, which might provide a favorable benefit-risk balance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                  <jats:p>Chinese Clinical Trial Registry, ChiCTR2100054588; IRB Approved: Ethics committee of Fudan University Shanghai Cancer Center (Date 2015.8.31\/No. 1508151-13.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae108","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:25:13Z","timestamp":1717208713000},"page":"819-e1223","source":"Crossref","is-referenced-by-count":3,"title":["Phase 2 study\u00a0of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine\/vindesine, and prednisone in newly diagnosed PTCL: 8-year results"],"prefix":"10.1093","volume":"29","author":[{"given":"Zu-Guang","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun-Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"},{"name":"Fudan University Shanghai Cancer Center Department of Radiology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"},{"name":"Fudan University Shanghai Cancer Center Department of Nuclear Medicine, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiu","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"},{"name":"Fudan University Shanghai Cancer Center Department of Pathology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wen","sequence":"additional","affiliation":[{"name":"School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University Department of Biostatistics, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University Department of Biostatistics, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Nan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[{"name":"Tongji University School of Medicine Department of Oncology, Shanghai East Hospital, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ning","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People\u2019s Republic of China"},{"name":"Shanghai Medical College, Fudan University Department of Oncology, , Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"4","key":"2024090704203769200_CIT0001","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024090704203769200_CIT0002","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imag"},{"issue":"10","key":"2024090704203769200_CIT0003","first-page":"897","article-title":"Comparative study on the efficacy of hyper CVAD\/MA regimen and CHOP or CHOP like regimen in the treatment of primary peripheral T cell lymphoma","volume":"35","author":"Wang","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"2024090704203769200_CIT0004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024090704203769200_CIT0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1430.15810","article-title":"Therapeutic effects and influencing factors in sixty-eight cases of peripheral T-cell lymphoma unspecified","volume":"100","author":"Kangsheng","year":"2014","journal-title":"Tumori"},{"issue":"3","key":"2024090704203769200_CIT0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024090704203769200_CIT0007","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2024090704203769200_CIT0008","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"18","key":"2024090704203769200_CIT0009","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10168","key":"2024090704203769200_CIT0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2024090704203769200_CIT0011","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"2024090704203769200_CIT0012","first-page":"e202","article-title":"The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: a single-institution analysis of 240 Chinese patients","volume":"19","author":"Chen","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"2024090704203769200_CIT0013","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024090704203769200_CIT0014","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.14763","article-title":"The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers","volume":"178","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"key":"2024090704203769200_CIT0015","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"issue":"25","key":"2024090704203769200_CIT0016","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024090704203769200_CIT0017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2024090704203769200_CIT0018","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12185-020-02987-7","article-title":"Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma","volume":"112","author":"Suzuki","year":"2020","journal-title":"Int J Hematol"},{"issue":"8","key":"2024090704203769200_CIT0019","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2021.1894649","article-title":"Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population","volume":"62","author":"Shirouchi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"36","key":"2024090704203769200_CIT0020","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"international assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024090704203769200_CIT0021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/1042819031000063471","article-title":"A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"44","author":"Pangalis","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024090704203769200_CIT0022","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"2024090704203769200_CIT0023","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6600346","article-title":"Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients","volume":"86","author":"Nousiainen","year":"2002","journal-title":"Br J Cancer"},{"issue":"10","key":"2024090704203769200_CIT0024","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/annonc\/mdt289","article-title":"Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma","volume":"24","author":"Herbrecht","year":"2013","journal-title":"Ann Oncol"},{"issue":"suppl_1","key":"2024090704203769200_CIT0025","doi-asserted-by":"crossref","first-page":"ehy565. P1582","DOI":"10.1093\/eurheartj\/ehy565.P1582","article-title":"P1582 early detection and prediction of CHOP-induced cardiotoxicity through 3D myocardial deformation, arterial stiffness and cardiac biomarkers in non-Hodgkin lymphoma","volume":"39","author":"Mihalcea","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"2024090704203769200_CIT0026","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/BF01249624","article-title":"Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis","volume":"23","author":"Gottsauner-Wolf","year":"1996","journal-title":"Eur J Nucl Med"},{"issue":"14","key":"2024090704203769200_CIT0027","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2024090704203769200_CIT0028","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/819\/59036670\/oyae108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/819\/59036670\/oyae108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:02:48Z","timestamp":1725685368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/9\/819\/7686138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,31]]},"published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae108","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,31]]}}}